Melanoma TrialFinder

For professionals

Find a trial

19 trials in 46 locations

ARTISTRY-6: A Phase 2, Open-label, Multicentre, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy

This study observes the anti-tumour activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy [...]

Locations: Oxford University Hospitals NHS Foundation Trust (PI: Prof. Mark Middleton), THE ROYAL MARSDEN HOSPITAL (LONDON) (PI: James Larkin), The Christie NHS Foundation Trust (PI: Avinash Gupta)

PORTSIDE: A Phase 2, Randomized, Open-Label Study of Encorafenib and Binimetinib plus Pembrolizumab versus Nivolumab and Ipilimumab in Participants with BRAF V600E/K Mutation-positive Melanoma Who Progressed During or After Prior Treatment with Anti-PD-1 Therapy

The purpose of this study is to learn about the effects of 3 study medicines (encorafenib, binimetinib, pembrolizumab) compared to 2 study medicines (ipilimumab and nivolumab) given for the treatment of melanoma.Melanoma is a type of cancer that starts in the cells that give colour to your skin.The study is seeking participants who: • have advanced or metastatic melanoma (has spread to other parts of the body); • have a certain abnormal gene called [...]

Locations: Nottingham University Hospitals NHS Trust (PI: Hester Franks), The Royal Marsden Hospital (LONDON) (PI: James Larkin), The Royal Marsden Hospital (SURREY) (PI: James Larkin)

HARMONY ADJUVANT STUDY: A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma

The primary objective of the study is to demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by relapse free survival (RFS)The secondary objectives of the study are: • To demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by overall survival (OS) • To demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by melanoma specific survival (MSS) • To evaluate whether post-operative adjuvant therapy improves distant [...]

Locations: The Christie NHS Foundation Trust (PI: Patricio Serra-Bellver), Western General Hospital (PI: Mark Stares), Barts Health NHS Trust (PI: Sukaina Rashid), Royal Devon and Exeter Hospital (Wonford) (PI: Kate Scatchard), The Royal Marsden Hospital (LONDON) (PI: James Larkin), Musgrove Park Hospital (PI: Clare Barlow), Bristol Haematology and Oncology Centre (PI: Christopher Herbert)

R3767-ONC-2011: A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

The primary objective of the study is to demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by progression-free survival (PFS)The secondary objectives of the study are: • To demonstrate superiority of fianlimab (REGN3767) + cemiplimab compared to pembrolizumab, as measured by overall survival (OS) • To demonstrate superiority in objective response rate (ORR) with fianlimab + cemiplimab compared to pembrolizumab • To characterize ORR, PFS, and OS with fianlimab + cemiplimab [...]

Locations: St James's University Hospital (PI: Jane Hook), Castle Hill Hospital (PI: Anthony Maraveyas), Royal Surrey County Hospital (PI: Panagiotis Koliou), Royal Devon and Exeter Hospital (PI: Kate Scatchard)

V940-001: A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma

The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning. [...]

Locations: Norfolk and Norwich University Hospital (PI: Jenny Nobes), Cambridge University Hospitals NHS Trust (PI: Pippa Corrie), Bristol Haematology and Oncology Centre (PI: Chris Herbert), The Royal Marsden Hospital (LONDON) (PI: James Larkin), University College Hospitals NHS Foundation Trust (PI: Heather Shaw)

TebeMRD: A Phase II Non-Randomized, Open-label, Multi-centre Study of the Safety and Efficacy of Tebentafusp in Melanoma With Molecular Relapsed Disease

Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma.This research study is investigating using a new blood test to decide when to give a drug called tebentafusp. Tebentafusp has been used in clinical trials in patients with advanced cutaneous and uveal melanoma. This study is designed to determine if tebentafusp can help patients with cutaneous or uveal melanoma [...]

Locations: Cambridge University Hospitals NHS Trust (SCREENING ONLY - treatment would be at Oxford) (PI: Pippa Corrie), University College London Hospitals NHS Foundation Trust (PI: Heather Shaw), Mount Vernon Cancer Centre (PI: Paul Nathan), Oxford University Hospitals NHS Foundation Trust (PI: Mark Middleton), The Clatterbridge Cancer Centre (PI: Joseph Sacco), The Beatson West of Scotland Cancer Centre (PI: Pavlina Spiliopoulou), Weston Park Hospital (SCREENING ONLY - treatment would be at another hospital on this list) (PI: Sarah Danson), The Christie NHS Foundation Trust (PI: Rebecca Lee)

MITRE: An Observational Study to Evaluate the Microbiome as a Biomarker of Efficacy and Toxicity in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy

This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer. [...]

Locations: Velindre Cancer Centre (Cardiff) (PI: Ricky Frazer), Weston Park Hospital (Sheffield) (PI: Sarah Danson), Addenbrookes Hospital (Cambridge) (PI: Pippa Corrie), Royal Surrey County Hospital (PI: Mazhar Ajaz), Poole Hospital (PI: Tom Geldart), , Western General Hospital (Edinburgh) (PI: Ewan Brown), Royal Cornwall Hospital (PI: Toby Talbot), Somerset NHS Foundation Trust (PI: Clare Barlow), The Queen Elizabeth Hospital King's Lynn (PI: Kamalram Thippu Jayaprakash), Bristol Haematology and Oncology Centre (PI: Helen Winter), University Hospital Southampton (PI: Matthew Wheater), Royal United Hospital Bath (PI: Tania Tillett), Royal Bournemouth Hospital (PI: Tom Geldart)

THETIS (ATX-ME-001): An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Metastatic or Recurrent Melanoma

This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the safety and clinical activity of ATL001, autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with metastatic or recurrent melanoma. [...]

Locations: University College London Hospital (UCLH) (PI: Heather Shaw), The Royal Marsden Hospital (LONDON) (PI: Andrew Furness), Cambridge University Hospitals NHS Foundation Trust (PI: Brent O'Carrigan), University Hospital Southampton (PI: Ioannis Karydis), Guys and St Thomas's NHS Foundation Trust (PI: Rebecca Kristeleit), Freeman Hospital (PI: Ruth Plummer), The Christie NHS Foundation Trust (PI: Fiona Thistlethwaite)

DANTE: Duration of Anti-PD1 therapy for melanoma

This trial aims to determine whether anti-PD1 monotherapy to treat advanced melanoma can be stopped after 1 year, rather than the current standard practice (i.e. continuing to treat until disease progression/unacceptable toxicity, or for at least 2 years), and achieve and maintain as good an outcome (in terms of the cancer coming back). The hypothesis is that continuing treatment beyond 1 year is unnecessary, as there is no biological evidence that justifies continuous therapy; [...]

Locations: This trial is no longer recruiting new patients

MISST: Melanoma Immunomodulation and Immune Responses of the Skin Study: A Translational Science Research Protocol

In this study we aim to investigate the nature of immune responses in human skin and in melanoma and to utilise these insights in order to explore potential novel treatment and clinical management avenues to benefit patients. T cells, B cells and other inflammatory and cytotoxic cells, such as monocytes and macrophages, found in the circulation and the tumour lesions of patients with melanoma will be investigated and compared with those from healthy volunteers.We [...]

Locations: Guy's and St Thomas' NHS Trust (PI: Sean Whittaker)

MelMarT-II: Melanoma Margins Trial-II - A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in [...]

Locations: Hull University Teaching Hospitals NHS Trust (PI: Paolo Matteucci), Oxford University Hospitals NHS Foundation Trust (PI: Oliver Cassell), The Christie NHS Foundation Trust (PI: Deemesh Oudit), Imperial College Healthcare NHS Trust (PI: Jonathan Dunne), Royal Preston Hospital (PI: Mr Richard Wain), Royal Cornwall Hospital (PI: Polly King), Nottingham University Hospitals NHS Trust (PI: Jonathan Pollock), Cambridge University Hospitals NHS Trust (PI: Amit Roshan and Amer Durrani), The Royal Marsden NHS Foundation Trust (PI: Myles Smith), Norfolk and Norwich University Hospital (PI: Prof Marc Moncrieff), The Leeds Teaching Hospitals NHS Trust (PI: Howard Peach), St George's University Hospitals NHS Foundation Trust (PI: Joy Odili), University Hospitals Birmingham NHS Foundation Trust (PI: Dr Agustin Martin-Clavijo), Mid and South Essex NHS Trust (PI: Professor Peter Dziewulski), Mersey and West Lancashire Teaching Hospitals NHS Trust (PI: Prof Rowan Pritchard Jones), South Tees Hospitals NHS Foundation Trust of The James Cook University Hospital (PI: Oliver Bassett), North Bristol NHS Trust (PI: Ewan Wilson), Royal Free London NHS Foundation Trust (PI: Stephen Hamilton), Guys and St Thomas' NHS Foundation Trust (PI: Hawys Lloyd-Hughes)

TEBE-AM: Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma

To evaluate the efficacy and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma [...]

Locations: Queen Elizabeth Hospital Birmingham (PI: Lalit Pallan), Mount Vernon Hospital (PI: Paul Nathan), Addenbrookes Hospital (PI: Pippa Corrie)

REFINE: REduced Frequency ImmuNE Checkpoint Inhibition in Cancers: A Multi Arm Phase II Basket Protocol Testing Reduced Intensity Immunotherapy Across Different Cancers

The REFINE trial aims to asses whether giving an immunotherapy drug less-often to patients with advanced cancer, results in fewer side effects whilst continuing to be an effective treatment. The question will be assessed in different tumour types by means of different cohorts within an overarching trial protocol. [...]

Locations: Royal Preston Hospital (PI: Natalie Charnley), Velindre Cancer Centre (PI: Ricky Frazer), The Beatson West of Scotland Cancer Centre (PI: Pavlina Spiliopoulou), The Royal Marsden Hospital (SURREY) (PI: Lisa Pickering), The Royal Marsden Hospital (LONDON) (PI: Lisa Pickering), Musgrove Park Hospital (PI: Gihan Ratnayake), Addenbrooke's Hospital (PI: Brent O’Carrigan), Western General Hospital (PI: Mark Stares), The Queen Alexandra Hospital (PI: Joanna Gale)

OOB: The Liverpool Ocular Oncology Biobank

The Liverpool Ocular Oncology Biobank (OOB) works closely with local and regional hospitals to collect and store ocular biosamples, blood and associated clinical data from consenting patients for use in research relating to eye cancers and other eye diseases. By doing this, the biobank can build a valuable collection that will be used by research groups across the world to address key basic and clinical research questions necessary to improve the healthcare of future [...]

Locations: The Liverpool Ocular Oncology Centre (PI: Dr Helen Kalirai (Biobank Custodian))

MYMELANOMA: The MyMelanoma Research Study

THIS IS A PATIENT, SELF-REFERRAL, ONLINE STUDYPatients can sign up at the MyMelanoma website www.mymelanomastudy.orgThe MyMelanoma project aims to build the world’s biggest melanoma database which will support research into melanoma all over the world.There are currently many researchers all over the world working to make things better for melanoma patients, however they are mostly working on small studies. In order to make faster progress these researchers need more information, both more detailed and [...]

Locations: This is an online study; anyone in the UK can take part.

The SCOPE Study: The SCOPE Study: SCIB1 and iSCIB1+ with immunotherapy for advanced melanoma

The purpose of this study is to find out if a new treatment cancer vaccine called SCIB1 can be used safely when added to either nivolumab (Opdivo) with ipilimumab (Yervoy) or pembrolizumab (Keytruda), standard treatments approved for patients with advanced melanoma (skin cancer).The study will also look to see if SCIB1 can increase the likelihood that melanoma patients will respond to either nivolumab with ipilimumab or pembrolizumab, and also if SCIB1 can help to [...]

Locations: Weston Park Hospital (PI: Sarah Danson), Royal Free London NHS Foundation Trust (PI: Amna Sheri), Derriford Hospital (PI: Martin Highley), Royal Preston Hospital (PI: Kellati Prasad), Somerset NHS Foundation Trust (PI: Gihan Ratnayake), Mount Vernon Hospital, East and North Hertfordshire NHS Trust (PI: Heather Shaw), Guys and St Thomas' NHS Foundation Trust (PI: Amanda Fitzpatrick), Oxford University Hospitals NHS Foundation Trust (PI: Miranda Payne), Velindre University NHS Trust (PI: Satish Kumar), Nottingham University Hospitals NHS Trust (PI: Poulam Patel), University Hospital Southampton (PI: Ioannis Karydis)

MAAM Study: The use of Microwave Ablation in the treatment of advanced melanoma with cutaneous metastases. An observational study using Emblation's microwave based treatment system SwiftTM

This is a pilot study to establish if MWA can successfully treat metastatic melanoma deposits using the Swift device manufactured by Emblation. As a control group, they will also test whether MWA can treat other skin lesions where standard surgical management is not recommended (including other skin cancer metastases, viral warts). The hypothesis is that precise directed delivery of microwave energy onto a melanoma deposit will lead to its destruction. In this biomarker [...]

Locations: University Hospital Southampton (PI: Danny O'Driscoll (study coordinator))